02.10.2015 Views

studies

2015SupplementFULLTEXT

2015SupplementFULLTEXT

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

1372A CATEGORY INDEX HEPATOLOGY, October, 2015<br />

Hepatic Decompensation After 412<br />

Hepatocellular Carcinoma Can 361<br />

Hepatocellular carcinoma has 445<br />

Hepatocellular carcinoma in 462<br />

Higher Incidence of Hepatoce 458<br />

Higher Risk for Hepatocellul 388<br />

Identification of candidate 384<br />

Identification of novel biom 358<br />

Impact of Viral Hepatitis Et 483<br />

Impact of screening on Hepat 404<br />

Improved Survival of Hepatoc 457<br />

Integrator complex subunit 6 375<br />

Korean validation and compar 452<br />

Liver Transplant Recipients 414<br />

Long non-coding RNA integrat 353<br />

Long-term Survival Analysis 474<br />

Multicentric Study of Liver 469<br />

Mutations of p53, ARID1A and 347<br />

Myeloid-derived suppressor c 392<br />

Natural history of portal ve 393<br />

Nucleos(t)ide analogue thera 345<br />

Overexpression of periostin 403<br />

Plasma MicoRNA-122 level as 379<br />

Prediction of Recurrence aft 363<br />

Preventive Effect of Urea-ba 354<br />

Pro-angiogenic Tie2-expressi 476<br />

Prospective cohort study for 455<br />

Racial Differences in the Pr 386<br />

Racial Disparity in Hepatoce 420<br />

Regional and Etiological Dif 459<br />

Skeletal muscle depletion as 477<br />

Small intrahepatic cholangio 487<br />

Sorafenib Therapy in HIV-inf 438<br />

Stereotactic body radiation 484<br />

Surgical resection versus ra 432<br />

Surveillance for Hepatocellu 360<br />

Survival and prognostic fact 485<br />

Survival of Patients with Ad 395<br />

Survival of Patients with Ad 448<br />

The Casein kinase II (CK2) i 396<br />

The ITA.LI.CA Staging System 356<br />

The presence of histological 466<br />

The prognosis and the recurr 453<br />

The radiofrequency ablation 385<br />

The relationship between the 443<br />

Trends of Hepatocellular Car 380<br />

Validation of the Metroticke 446<br />

Value of PIVKA II and AFP se 480<br />

Variability in False-Positiv 427<br />

Vitamin K dosing during sora 173<br />

Hepatotoxicity<br />

HO1. Pathogenesis and Mechanisms<br />

A comparative analysis of th 595<br />

A protective role of C/EBP h 592<br />

Caspase Inhibition Switched 598<br />

Differentially altered gut m 581<br />

Golgi Stress Response Is Ass 588<br />

HMGB1-driven Feedforward Hep 178<br />

Inhibition of NF-kB by deoxy 176<br />

Oxaloacetic Acid Protects th 179<br />

Phenotypic and genotypic cha 583<br />

Sumoylation Regulates Lipopo 594<br />

The Clinical-Pathological Sp 597<br />

The Hepatic “Matrisome” 587<br />

The influence of drug proper 596<br />

Transcriptomic Analysis Of H 175<br />

Acetaldehyde Triggers HCV-In 589<br />

Critical role of sirtuin 1-m 177<br />

EPAC mediated protection aga 582<br />

Effect of Branched Chain Ami 584<br />

Hormesis in cholestatic live 591<br />

Mitochondrial Fission Factor 590<br />

Mitochondrial-shaping protei 599<br />

Persistent Generation of Inf 585<br />

Protective effects of connex 586<br />

STING deficiency protects fr 180<br />

The Effect of Treatment with 593<br />

HO2. Drug Metabolism, Toxicity, and<br />

Therapeutics<br />

3D culture strategies for im 1921<br />

AMPK activation prevents and 1909<br />

Application of the Drug-Indu 1929<br />

Caffeine Confers Hepatoprote 1917<br />

Combined Activities of JNK1 1924<br />

Drug-Induced Liver Injury As 1920<br />

Gab1 adaptor protein is an e 227<br />

Gender-specific glucuronidat 1927<br />

Long-term Outcome of HIV+ Pa 1908<br />

Protective role of miR-122 a 99<br />

Severe and prolonged jaundic 1923<br />

Sodium 4-phenylbutyric acid 226<br />

Statins prevent liver tumor 1919<br />

The non-nucleoside reverse t 1913<br />

Transcriptional Profiling Of 1916<br />

A Rapid Test for Acetaminoph 1914<br />

Azathioprine And 6-Mercaptop 1926<br />

Death and Liver Transplantat 1922<br />

Drug Induced Liver Injury (D 1928<br />

Human mercapto-albumin level 1912<br />

Intervention of RIPK-depende 1918<br />

Rescue of hepatocytes from l 223<br />

The role of CD36 in acetamin 1910<br />

Translocation of Iron from L 1925<br />

Understanding the Relationsh 1915<br />

Withaferin-A Reduces Acetami 1911<br />

HO3. Predictors of Drug Toxicity<br />

HLA-A*33:01 is strongly asso 225<br />

Genome-wide investigation id 1933<br />

Lipotoxicity Accounts for Li 228<br />

Minocycline hepatotoxicity: 1930<br />

Predicting In Vivo Hepatotox 224<br />

Liver Disorders that can Mas 1931<br />

The Epidemiology of Suspecte 1932<br />

Human Cholestatic<br />

and Autoimmune Liver<br />

Diseases<br />

IO1. PBC/PSC and Other Cholestatic<br />

Disease<br />

Association between elevated 616<br />

Bezafibrate: A novel and eff 603<br />

CD39 expression regulates Th 608<br />

Characterization Of A Patien 630<br />

Cholestatic liver disease an 631<br />

Clinical Epidemiology of Pri 75<br />

Colectomy is associated with 622<br />

Combination Anti-Retroviral 641<br />

Elevation of alkaline phosph 634<br />

Emperipolesis mediated by CD 638<br />

Enhanced and Prolonged FGF19 604<br />

Expression of matrix metallo 632<br />

Gender and IBD phenotype are 76<br />

Ig Repertoire of Autoantigen 77<br />

Impact of NGM282 on the Inci 627<br />

Incidence and Impact of Deco 73<br />

Increased expression of ORM1 614<br />

Integrated Analysis of Effic 645<br />

Long-term follow-up of a mul 605<br />

Long-term safety and efficac 628<br />

NGM282, A Novel Variant of F 106<br />

Patients with Primary Biliar 610<br />

Patients with childhood-onse 600<br />

Phenotypic Variations in Pri 607<br />

S-Alkaline phosphatase is no 633<br />

Sustained Improvement in the 609<br />

The IgG/IgG4 mRNA ratio by q 637<br />

The prevalence and outcomes 626<br />

Thyroid dysfunction in prima 629<br />

Validation of serum fibrosis 624<br />

A Novel Prognostic Model for 74<br />

Alkaline Phosphatase as Biom 623<br />

Clinician confidence in stra 636<br />

Convergence of Two Predictiv 601<br />

Differentially Expressed Pla 602<br />

Down-regulation of the secre 621<br />

Efficacy and Safety of Obeti 625<br />

Evaluation of the Posology o 635<br />

Gene expression profiling of 615<br />

High-risk primary biliary ci 611<br />

In PSC with dominant bile du 618<br />

Innate Immunity Drives the I 619<br />

Intrahepatic Cholestasis of 78<br />

Long term impact of fibrates 642<br />

Long-Term Safety of OCA in P 644<br />

Modeling biliary fluid dynam 617<br />

Natural killer cells regulat 640<br />

Phenotypic and Cytotoxic Ana 639<br />

Predictors of recurrence and 643<br />

Serum metabolomic profile of 620<br />

The Modulation of Co-stimula 613<br />

Unique Immunologlobulin Glyc 606<br />

Vitamin A deficiency promote 612<br />

IO2. Autoimmune Liver Disease<br />

Autoimmune hepatitis type 1 302<br />

Features and patterns of con 312<br />

Impact of SNP rs2187668 in H 297<br />

In autoimmune liver disease 300<br />

Killer cell immunoglobulin-l 309<br />

Macrophage migration inhibit 298<br />

Mean Corpuscular Volume as S 303<br />

Possible involvement of acti 310<br />

Soluble PD-1 levels are asso 301<br />

Tacrolimus or Mycophenylate 308<br />

Autoimmune Hepatitis Disprop 306<br />

Carcinogenesis in autoimmune 304<br />

Immunity in HLA-DR4 expressi 305<br />

Methotrexate therapy for Aut 311<br />

Outcomes and mortality of de 307<br />

Plasma levels of heparanase 299

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!